Small-Format Drug Conjugates: A Viable Alternative to ADCs for Solid Tumours?

Small-Format Drug Conjugates: A Viable Alternative to ADCs for Solid Tumours?

Antibody–Drug Conjugates (ADCs) have been through multiple cycles of technological innovation since the concept was first practically demonstrated ~40 years ago. Current technology is focusing on large, whole immunoglobulin formats (of which there are approaching 100 in clinical development), many w...

Full description

Bibliographic Details
Main Authors: Mahendra P. Deonarain, Gokhan Yahioglu, Ioanna Stamati, Anja Pomowski, James Clarke, Bryan M. Edwards, Soraya Diez-Posada, Ashleigh C. Stewart
Format: Article
Language:English
Published: MDPI AG 2018-03-01
Series:Antibodies
Subjects:
antibody–drug conjugate
fragment
alternative scaffold
penetration
pharmacokinetics
Online Access:http://www.mdpi.com/2073-4468/7/2/16

Internet

http://www.mdpi.com/2073-4468/7/2/16

Similar Items